Chemotherapy with agents such as the anthracyclines and the taxanes remains a mainstay of breast cancer treatment, however improvement on these therapies is clearly needed. It is important to achieve a greater clinical benefit not only in patients who have developed resistance to these agents, but also in key patient sub-populations who have the worst prognosis. The papers in this supplement do not just highlight the problems faced when treating these patient groups, but provide some hope for the improvements we can expect from future therapies, including new cytotoxics.
ASJC Scopus subject areas
- Cancer Research